search
Back to results

Clinical Trial of New Hypothermic Oxygenated Perfusion System Versus Static Cold Storage

Primary Purpose

Liver Diseases, Kidney Diseases

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Kidney-Hypothermic oxygenated
Liver-Hypothermic oxygenated
Sponsored by
University of Bologna
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Liver Diseases focused on measuring donors and donation, Extended criteria donor, Organ perfusion and preservation, Liver transplantation, Kidney transplantation, Preservation injury, Ischemia reperfusion injury

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • For kidneys: donor age ≥ 60 years or 50-59 years with two or more of the sequent risk factors: death due to cerebrovascular accident, history of hypertension, donor serum creatinine > 1.5 mg/dL, cold ischemia time (CIT) > 20 h;
  • For livers: donors with hemodynamic deterioration, donor age > 65 years, donor body mass index > 30 kg/m2, serum bilirubin > 3 mg/dl, AST or ALT above three times the upper reference threshold, sodium > 165 mmol/l, intensive care unit (ICU) stay > 7 days, steatosis > 40%, CIT > 12 h.

Exclusion Criteria:

  • Donor age ≤18 years;
  • Donors after circulatory death (DCD) will be excluded, because Italian law requires 20 minutes of "no touch period" before death declaration, causing prolonged warm ischemia and subsequent mandatory perfusion of the organ.
  • Split-liver recipients, liver transplantation (LT) for acute liver failure, pre-emptive renal transplant, dual kidney transplantation, and patients with intra-operative surgical complications before the organ implantation.

Sites / Locations

  • Azienda Ospedaliera di Bologna - Policlinico S. Orsola MalpighiRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

No Intervention

Experimental

No Intervention

Arm Label

Kidney-Hypothermic oxygenated

Kidney-Static Cold Storage

Liver-Hypothermic oxygenated

Liver-Static Cold Storage

Arm Description

Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 2000 ml for kidneys.

Kidneys undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.

Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 3000 ml for livers.

Livers undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.

Outcomes

Primary Outcome Measures

Liver Transplant - Early allograft dysfunction (EAD)
Present/Non present
Kidney Transplant- Delayed graft function (DGF)
Present/Non present

Secondary Outcome Measures

Liver and Kidney surgical complications
Present/Non present
Liver and Kidney graft function at 6 and 12 months
Functioning/non functioning
Patient survival at 6 and 12 months
Alive/Death

Full Information

First Posted
February 5, 2019
Last Updated
September 25, 2019
Sponsor
University of Bologna
search

1. Study Identification

Unique Protocol Identification Number
NCT03837197
Brief Title
Clinical Trial of New Hypothermic Oxygenated Perfusion System Versus Static Cold Storage
Official Title
Expanded Criteria Donors in Liver and Kidney Transplantation: Protocol of a Randomised Single Center Clinical Trial of Hypothermic Oxygenated Perfusion Versus Static Cold Storage
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Unknown status
Study Start Date
December 21, 2018 (Actual)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
December 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Bologna

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
With the present study the investigators will evaluate the benefit of end-ischemic HOPE on ECD grafts (livers and kidneys) as compared to SCS. Organs will be perfused through a recently developed machine perfusion (MP) device, from the beginning of back-table procedures till implantation, without increasing CIT. The aim of the study will be demonstrating the ability of HOPE to improve graft function and post-operative outcomes of ECD kidney and liver recipients.
Detailed Description
Extended criteria donors (ECD) are widely utilized due to organ shortage, but this may increase the risk of graft dysfunction and of poorer outcomes. Hypothermic oxygenated perfusion (HOPE) is a recent organ preservation strategy for marginal kidney and liver grafts, which allows to redirect anaerobic metabolism to aerobic metabolism under hypothermic conditions and to protect grafts from oxidative species-related damage; these mechanisms may potentially improve graft function and survival. Methods This is an open-label, randomized multicenter clinical trial with the aim of comparing HOPE vs. static cold storage (SCS) in ECD kidney and liver transplantation. In the study protocol - approved by ethics committee - 220 patients (110 liver recipients and 110 kidney recipients) will be enrolled. Livers and kidneys assigned to HOPE will be perfused by machine perfusion with cold Belzer solution (4°-10°C) and with continuous oxygenation (partial pressure of oxygen = 500-600 mmHg). In the control group, livers and kidneys undergoing SCS will be steeped in Celsior or University of Wisconsin Belzer solutions and stored in ice. Using the same perfusion machine for both liver and kidney grafts, organs will be perfused from the start of the back-table procedure until implantation, without increasing cold ischemia time (CIT). For each group the investigators will evaluate clinical outcomes, graft function tests and histologic findings, as well as perfusate and the number of allocated organs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Diseases, Kidney Diseases
Keywords
donors and donation, Extended criteria donor, Organ perfusion and preservation, Liver transplantation, Kidney transplantation, Preservation injury, Ischemia reperfusion injury

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
220 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Kidney-Hypothermic oxygenated
Arm Type
Experimental
Arm Description
Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 2000 ml for kidneys.
Arm Title
Kidney-Static Cold Storage
Arm Type
No Intervention
Arm Description
Kidneys undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
Arm Title
Liver-Hypothermic oxygenated
Arm Type
Experimental
Arm Description
Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 3000 ml for livers.
Arm Title
Liver-Static Cold Storage
Arm Type
No Intervention
Arm Description
Livers undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
Intervention Type
Device
Intervention Name(s)
Kidney-Hypothermic oxygenated
Intervention Description
Kidney perfusion will be performed through the renal artery at 25-30 mmHg pressure. Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination. HOPE will start by flushing the organ at low flow values (20 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 2 hours for kidneys.
Intervention Type
Device
Intervention Name(s)
Liver-Hypothermic oxygenated
Intervention Description
Liver perfusion will be performed through the portal vein at a 5 mmHg pressure. Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination. HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers.
Primary Outcome Measure Information:
Title
Liver Transplant - Early allograft dysfunction (EAD)
Description
Present/Non present
Time Frame
0-30 days after procedure
Title
Kidney Transplant- Delayed graft function (DGF)
Description
Present/Non present
Time Frame
0-30 days after procedure
Secondary Outcome Measure Information:
Title
Liver and Kidney surgical complications
Description
Present/Non present
Time Frame
0-6 months after procedure
Title
Liver and Kidney graft function at 6 and 12 months
Description
Functioning/non functioning
Time Frame
0-12 months after procedure
Title
Patient survival at 6 and 12 months
Description
Alive/Death
Time Frame
0-12 months after procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: For kidneys: donor age ≥ 60 years or 50-59 years with two or more of the sequent risk factors: death due to cerebrovascular accident, history of hypertension, donor serum creatinine > 1.5 mg/dL, cold ischemia time (CIT) > 20 h; For livers: donors with hemodynamic deterioration, donor age > 65 years, donor body mass index > 30 kg/m2, serum bilirubin > 3 mg/dl, AST or ALT above three times the upper reference threshold, sodium > 165 mmol/l, intensive care unit (ICU) stay > 7 days, steatosis > 40%, CIT > 12 h. Exclusion Criteria: Donor age ≤18 years; Donors after circulatory death (DCD) will be excluded, because Italian law requires 20 minutes of "no touch period" before death declaration, causing prolonged warm ischemia and subsequent mandatory perfusion of the organ. Split-liver recipients, liver transplantation (LT) for acute liver failure, pre-emptive renal transplant, dual kidney transplantation, and patients with intra-operative surgical complications before the organ implantation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Matteo Ravaioli, PhD
Phone
0512144810
Ext
+39
Email
mrava1@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matteo Ravaioli, PhD
Organizational Affiliation
University of Bologna S.Orsola-Malpighi Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Azienda Ospedaliera di Bologna - Policlinico S. Orsola Malpighi
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matteo Ravaioli, PhD
Phone
0512144810
Email
mrava1@hotmail.com
First Name & Middle Initial & Last Name & Degree
Matteo Ravaioli, PhD

12. IPD Sharing Statement

Citations:
PubMed Identifier
3282347
Citation
Belzer FO, Southard JH. Principles of solid-organ preservation by cold storage. Transplantation. 1988 Apr;45(4):673-6. doi: 10.1097/00007890-198804000-00001. No abstract available.
Results Reference
background
PubMed Identifier
25470081
Citation
Tanrisev M, Hoscoskun C, Asci G, Sozbilen M, Firat O, Ertilav M, Ozkahya M, Toz H. Long-term outcome of kidney transplantation from elderly living and expanded criteria deceased donors. Ren Fail. 2015 Mar;37(2):249-53. doi: 10.3109/0886022X.2014.982488. Epub 2014 Dec 3.
Results Reference
background
PubMed Identifier
16539636
Citation
Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, Greenstein SM, Merion RM. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006 Apr;6(4):783-90. doi: 10.1111/j.1600-6143.2006.01242.x. Erratum In: Am J Transplant. 2018 Dec;18(12):3085.
Results Reference
background
PubMed Identifier
29326416
Citation
Ravaioli M, Baldassare M, Vasuri F, Pasquinelli G, Laggetta M, Valente S, De Pace V, Neri F, Siniscalchi A, Zanfi C, Bertuzzo VR, Caraceni P, Trere D, Longobardi P, Pinna AD. Strategies to Restore Adenosine Triphosphate (ATP) Level After More than 20 Hours of Cold Ischemia Time in Human Marginal Kidney Grafts. Ann Transplant. 2018 Jan 12;23:34-44. doi: 10.12659/aot.905406.
Results Reference
background
PubMed Identifier
28928357
Citation
Ravaioli M, De Pace V, Comai G, Busutti M, Del Gaudio M, Amaduzzi A, Cucchetti A, Siniscalchi A, La Manna G, D'Errico AAD, Pinna AD. Successful Dual Kidney Transplantation After Hypothermic Oxygenated Perfusion of Discarded Human Kidneys. Am J Case Rep. 2017 Sep 20;18:1009-1013. doi: 10.12659/ajcr.905377.
Results Reference
background
PubMed Identifier
27584571
Citation
Kron P, Schlegel A, de Rougemont O, Oberkofler CE, Clavien PA, Dutkowski P. Short, Cool, and Well Oxygenated - HOPE for Kidney Transplantation in a Rodent Model. Ann Surg. 2016 Nov;264(5):815-822. doi: 10.1097/SLA.0000000000001766.
Results Reference
background
PubMed Identifier
29564206
Citation
Schlegel A, Muller X, Dutkowski P. Hypothermic Machine Preservation of the Liver: State of the Art. Curr Transplant Rep. 2018;5(1):93-102. doi: 10.1007/s40472-018-0183-z. Epub 2018 Jan 22. Erratum In: Curr Transplant Rep. 2018;5(1):103.
Results Reference
background
PubMed Identifier
26583664
Citation
Dutkowski P, Polak WG, Muiesan P, Schlegel A, Verhoeven CJ, Scalera I, DeOliveira ML, Kron P, Clavien PA. First Comparison of Hypothermic Oxygenated PErfusion Versus Static Cold Storage of Human Donation After Cardiac Death Liver Transplants: An International-matched Case Analysis. Ann Surg. 2015 Nov;262(5):764-70; discussion 770-1. doi: 10.1097/SLA.0000000000001473.
Results Reference
background
PubMed Identifier
12451266
Citation
Port FK, Bragg-Gresham JL, Metzger RA, Dykstra DM, Gillespie BW, Young EW, Delmonico FL, Wynn JJ, Merion RM, Wolfe RA, Held PJ. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation. 2002 Nov 15;74(9):1281-6. doi: 10.1097/00007890-200211150-00014.
Results Reference
background
PubMed Identifier
18492121
Citation
Attia M, Silva MA, Mirza DF. The marginal liver donor--an update. Transpl Int. 2008 Aug;21(8):713-24. doi: 10.1111/j.1432-2277.2008.00696.x. Epub 2008 May 19.
Results Reference
background
PubMed Identifier
29957863
Citation
Ravaioli M, De Pace V, Comai G, Capelli I, Baraldi O, D'Errico A, Bertuzzo VR, Del Gaudio M, Zanfi C, D'Arcangelo GL, Cuna V, Siniscalchi A, Sangiorgi G, La Manna G. Preliminary experience of sequential use of normothermic and hypothermic oxygenated perfusion for donation after circulatory death kidney with warm ischemia time over the conventional criteria - a retrospective and observational study. Transpl Int. 2018 Nov;31(11):1233-1244. doi: 10.1111/tri.13311. Epub 2018 Jul 20.
Results Reference
background
PubMed Identifier
20677285
Citation
Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, Shaked A, Christie JD. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010 Aug;16(8):943-9. doi: 10.1002/lt.22091.
Results Reference
background
PubMed Identifier
29261831
Citation
Agopian VG, Harlander-Locke MP, Markovic D, Dumronggittigule W, Xia V, Kaldas FM, Zarrinpar A, Yersiz H, Farmer DG, Hiatt JR, Busuttil RW. Evaluation of Early Allograft Function Using the Liver Graft Assessment Following Transplantation Risk Score Model. JAMA Surg. 2018 May 1;153(5):436-444. doi: 10.1001/jamasurg.2017.5040. Erratum In: JAMA Surg. 2018 May 1;153(5):498.
Results Reference
background
PubMed Identifier
12437622
Citation
Humar A, Ramcharan T, Kandaswamy R, Gillingham K, Payne WD, Matas AJ. Risk factors for slow graft function after kidney transplants: a multivariate analysis. Clin Transplant. 2002 Dec;16(6):425-9. doi: 10.1034/j.1399-0012.2002.02055.x.
Results Reference
background
PubMed Identifier
23063573
Citation
Schlegel A, de Rougemont O, Graf R, Clavien PA, Dutkowski P. Protective mechanisms of end-ischemic cold machine perfusion in DCD liver grafts. J Hepatol. 2013 Feb;58(2):278-86. doi: 10.1016/j.jhep.2012.10.004. Epub 2012 Oct 11.
Results Reference
background
PubMed Identifier
19845597
Citation
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155. doi: 10.1111/j.1600-6143.2009.02834.x.
Results Reference
background
PubMed Identifier
15645611
Citation
Versteilen AM, Di Maggio F, Leemreis JR, Groeneveld AB, Musters RJ, Sipkema P. Molecular mechanisms of acute renal failure following ischemia/reperfusion. Int J Artif Organs. 2004 Dec;27(12):1019-29. doi: 10.1177/039139880402701203.
Results Reference
result
PubMed Identifier
35671067
Citation
Ravaioli M, Germinario G, Dajti G, Sessa M, Vasuri F, Siniscalchi A, Morelli MC, Serenari M, Del Gaudio M, Zanfi C, Odaldi F, Bertuzzo VR, Maroni L, Laurenzi A, Cescon M. Hypothermic oxygenated perfusion in extended criteria donor liver transplantation-A randomized clinical trial. Am J Transplant. 2022 Oct;22(10):2401-2408. doi: 10.1111/ajt.17115. Epub 2022 Jun 21.
Results Reference
derived
PubMed Identifier
32191209
Citation
Ravaioli M, Maroni L, Angeletti A, Fallani G, De Pace V, Germinario G, Odaldi F, Corradetti V, Caraceni P, Baldassarre M, Vasuri F, D'Errico A, Sangiorgi G, Siniscalchi A, Morelli MC, Rossetto A, Ranieri VM, Cescon M, Del Gaudio M, Zanfi C, Bertuzzo V, Comai G, La Manna G. Hypothermic Oxygenated Perfusion Versus Static Cold Storage for Expanded Criteria Donors in Liver and Kidney Transplantation: Protocol for a Single-Center Randomized Controlled Trial. JMIR Res Protoc. 2020 Mar 19;9(3):e13922. doi: 10.2196/13922.
Results Reference
derived
Links:
URL
https://trapianti.sanita.it
Description
Sistema Informativo Trapianti (SIT)

Learn more about this trial

Clinical Trial of New Hypothermic Oxygenated Perfusion System Versus Static Cold Storage

We'll reach out to this number within 24 hrs